by: Parent Project Muscular Dystrophy
Wave Life Sciences recently joined PPMD for a community webinar to provide an update on the company’s Phase 2 FORWARD-53 trial of WVE-N531, Wave’s exon skipping oligonucleotide being investigated for the treatment of individuals with Duchenne who are amenable to exon 53 skipping. Wave discussed the recently released FORWARD-53 data and answered questions from the community.
